Introducing ‘Colo-Prevent’ Genomic Test

Block23’s first genomic test is Colo-Prevent, a clinically validated screen test for colorectal cancer (CRC), a disease with the 2nd highest occurrence of cancer. Utilizing only a home saliva kit, Block23 will offer screenings beginning in September 2018.

Based on genomic tests conducted on over 42,000 colorectal cancer patients, Colo-Prevent represents an accurate reading of risk and offers a guide for managing your health.

Download information

Apply for receiving the Colo-Prevent test